Written answers
Tuesday, 27 September 2016
Department of Health
National Cancer Strategy
Billy Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
540. To ask the Minister for Health to outline the position regarding the evaluation of Pembrolizumab; when he will make a decision on the introduction of this drug; and if he will make a statement on the matter. [26454/16]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
Pembrolizumab is currently available for reimbursement for the treatment of melanoma through the National Cancer Control Programme's Oncology Hospital Drugs Management System. Details of the protocol for eligibility and treatment are available at .
The HSE has also received an application for reimbursement of pembrolizumab for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC). The National Centre for Pharmacoeconomics recently completed a rapid review of pembrolizumab for this indication, and has recommended a full health technology assessment of the drug.
No comments